ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $220,374.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,772 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total transaction of $220,374.00. Following the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ori Gutwerg also recently made the following trade(s):

• On Tuesday, March 3rd, Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00.

ANI Pharmaceuticals Stock Down 2.0%

ANI Pharmaceuticals stock opened at $78.01 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52-week low of $56.71 and a 52-week high of $99.50. The firm has a 50 day moving average price of $77.29 and a two-hundred day moving average price of $80.48. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 19.75 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter last year, the business earned $1.70 EPS. The company’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Guggenheim lifted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.